ArticleProbiotics and antimicrobial proteins2026
Lactiplantibacillus plantarum AS21 Reduces Colitis in Mice by Modulating Inflammation, Gut Barrier Function, and Microbiota in an Intervention Dose and Time-dependent Manner.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Ulcerative colitis is a chronic inflammatory disease with rising global incidence and limited treatment options. Despite growing interest in probiotic-based therapies, the dose- and time-specific efficacy of antioxidant strains remains poorly defined. Here, we investigated the therapeutic effects of intervention doses (Low, Medium, High) and pre-treatment times (7, 14, 21 days) of Lactiplantibacillus plantarum AS21 on DSS-induced colitis in mice. L. plantarum AS21 significantly reduced disease activity index and histological scores, enhancing IL-10 expression while suppressing IL-1β, IL-6, TNF-α, and IFN-γ (p < 0.05). Colon length shortening was attenuated, and spleen weight was reduced in the treated groups. Oxidative stress markers MDA and MPO decreased, whereas SOD, CAT, and GSH increased in a dose- and time-dependent manner (p < 0.05). Mucosal barrier integrity was restored through claudin-1 and occludin upregulation and increased goblet cell counts (p < 0.05). Alpha diversity showed no significant differences, but beta diversity revealed significant separation across groups (p < 0.05). Beneficial taxa (Firmicutes, Ileibacterium, Allobaculum) were enriched, while pathogenic taxa (Akkermansia, Proteobacteria) were reduced in treated groups (p < 0.05). Anti-inflammatory metabolites (7-dehydrocholesterol, riboflavin, citric acid, lipid derivatives) and short-chain fatty acids were significantly upregulated (p < 0.05). Medium and high doses, together with 14- and 21-day pre-treatment, conferred significantly greater protective effects than 7-day pre-treatment or low-dose groups (p < 0.05). These findings establish precise dose- and time-dependent parameters for maximizing L. plantarum AS21 anti-colitic efficacy, positioning it as a promising candidate for microbiota- and metabolism-targeted UC therapy.
Indexed as
Identifiers
42118445What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.